BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 15771954)

  • 1. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
    Kowalski P; Surowiak P; Lage H
    Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
    Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavonoids inhibit breast cancer resistance protein-mediated drug resistance: transporter specificity and structure-activity relationship.
    Katayama K; Masuyama K; Yoshioka S; Hasegawa H; Mitsuhashi J; Sugimoto Y
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):789-97. PubMed ID: 17345086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Stein U; Scheffer GL; Lage H
    Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
    Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
    Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new intestinal cell culture model to discriminate the relative contribution of P-gp and BCRP on transport of substrates such as imatinib.
    Graber-Maier A; Gutmann H; Drewe J
    Mol Pharm; 2010 Oct; 7(5):1618-28. PubMed ID: 20701289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of efflux transporters on the transport of highly toxic aconitine, mesaconitine, hypaconitine, and their hydrolysates, as determined in cultured Caco-2 and transfected MDCKII cells.
    Ye L; Yang X; Yang Z; Gao S; Yin T; Liu W; Wang F; Hu M; Liu Z
    Toxicol Lett; 2013 Feb; 216(2-3):86-99. PubMed ID: 23200901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line.
    Farabegoli F; Papi A; Bartolini G; Ostan R; Orlandi M
    Phytomedicine; 2010 Apr; 17(5):356-62. PubMed ID: 20149610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obatoclax as a perpetrator in drug-drug interactions and its efficacy in multidrug resistance cell lines.
    Theile D; Allendorf D; Köhler BC; Jassowicz A; Weiss J
    J Pharm Pharmacol; 2015 Nov; 67(11):1575-84. PubMed ID: 26255619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
    Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
    Kovalev AA; Tsvetaeva DA; Grudinskaja TV
    Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
    Salphati L; Plise EG; Li G
    Eur J Pharm Sci; 2009 Jun; 37(3-4):463-8. PubMed ID: 19491037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
    Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
    Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier.
    Nagasaka Y; Oda K; Iwatsubo T; Kawamura A; Usui T
    Biopharm Drug Dispos; 2012 Sep; 33(6):304-15. PubMed ID: 22847220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
    Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
    Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.